Department of Neurosurgery, Stanford University Medical Center, 453 Quarry Road, Stanford, CA, 94304, USA.
School of Medicine, Stanford University, 291 Campus Drive, Stanford, CA, 94305, USA.
J Neurooncol. 2022 Jul;158(3):445-451. doi: 10.1007/s11060-022-04031-6. Epub 2022 May 21.
Stereotactic radiosurgery (SRS) to the surgical bed of resected brain metastases is now considered the standard of care due to its advantages over whole brain radiation therapy (WBRT). Despite the upward trend in SRS adoption since the 2000s, disparities have been reported suggesting that socio-economic factors can influence SRS utilization.
To analyze recent trends in SRS use and identify factors that influence treatment.
We conducted a retrospective cohort study with the Optum Commercial Claims and Encounters Database and included all patients from 2004 to 2021 who received SRS or WBRT within 60 days after resection of tumors metastatic to the brain.
A total of 3495 patients met the inclusion and exclusion criteria. There were 1998 patients in the SRS group and 1497 patients in the WBRT group. SRS use now supersedes WBRT by a wide margin. Lung, breast and colon were the most common sites of primary tumor. Although we found no significant differences based on race among the treatment groups, patients with annual household income greater than $75,000 and those with some college or higher education are significantly more likely to receive SRS (OR 1.44 and 1.30; 95% CI 1.18-1.76 and 1.08-1.56; P = 0.001 and 0.005, respective). Patients with Elixhauser Comorbidity Index of three or more were significantly more likely to receive SRS treatment.
The use of post-surgical SRS for brain metastasis has increased significantly over time, however education and income were associated with differential SRS utilization.
立体定向放射外科(SRS)治疗切除脑转移瘤的手术床现在被认为是标准治疗方法,因为它优于全脑放疗(WBRT)。尽管自 2000 年代以来 SRS 的采用率呈上升趋势,但据报道存在差异,表明社会经济因素可能会影响 SRS 的应用。
分析 SRS 使用的最新趋势,并确定影响治疗的因素。
我们使用 Optum 商业索赔和就诊数据库进行了回顾性队列研究,纳入了 2004 年至 2021 年期间所有接受 SRS 或 WBRT 的患者,这些患者在切除脑转移瘤后 60 天内接受了治疗。
共有 3495 名患者符合纳入和排除标准。SRS 组有 1998 例患者,WBRT 组有 1497 例患者。SRS 的使用现在已经大大超过了 WBRT。肺癌、乳腺癌和结肠癌是最常见的原发肿瘤部位。尽管我们在治疗组之间没有发现基于种族的显著差异,但年收入超过 75000 美元的患者和接受过一些大学或更高教育的患者接受 SRS 的可能性明显更高(OR 1.44 和 1.30;95%CI 1.18-1.76 和 1.08-1.56;P=0.001 和 0.005)。Elixhauser 合并症指数为三或更高的患者接受 SRS 治疗的可能性明显更高。
随着时间的推移,用于治疗脑转移瘤的术后 SRS 的使用显著增加,然而,教育和收入与 SRS 的应用差异有关。